UK Markets closed

Evgen Pharma plc (EVG.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
9.80+0.55 (+5.95%)
At close: 4:35PM GMT

Evgen Pharma plc

The Colony
Altrincham Road
Wilmslow SK9 4LY
United Kingdom
44 16 2546 6591
http://www.evgen.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees9

Key executives

NameTitlePayExercisedYear born
Mr. Richard Anthony MoulsonCFO & Exec. Director85.4kN/A1962
Dr. Huw JonesChief Exec. OfficerN/AN/A1960
Ms. Liz JenkinsRegulatory ConsultantN/AN/AN/A
Dr. Thomas MorrisConsultant & Medical Advisor of OncologyN/AN/AN/A
Prof. Albena Dinkova-KostovaIndependent Scientific AdvisorN/AN/AN/A
Prof. Giovanni MannIndependent Scientific AdvisorN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.

Corporate governance

Evgen Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.